Literature DB >> 31366509

High-signal-intensity MR Image in the Hepatobiliary Phase Predicts Long-term Survival in Patients With Hepatocellular Carcinoma.

Shun-Ichi Ariizumi1, Daisuke Ban2, Yuta Abe3, Takafumi Kumamoto4, Satoshi Koizumi5, Minoru Tanabe2, Masahiro Shinoda3, Itaru Endo4, Takehito Otsubo5, Masakazu Yamamoto6.   

Abstract

BACKGROUND/AIM: The aim of the study was to evaluate surgical outcomes of patients with high-signal intensity (SI) image hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Between 2008 and 2013, 257 HCC patients were retrospectively evaluated. A total of 21 patients were diagnosed as high-SI image HCC, 215 as low-SI image HCC, and 21 patients as mixed (high and low)-SI image HCC in the hepatobiliary (HB) phase of MRI. Five-year overall survival (OS) and recurrence-free survival (RFS) were compared among patient groups.
RESULTS: The 5-year OS and RFS rates were significantly higher in patients with high-SI image HCC (100% and 56%) than in patients with low-SI image HCC (71%; p=0.097 and 38%; p=0.0209) and in patients with mixed-SI image HCC (73%; p=0.0329 and 9%; p=0.0021). High-SI image was an independent prognostic factor for OS (relative risk 0.167, p=0.0178) and RFS (relative risk 0.471, p=0.0322) on multivariate analysis.
CONCLUSION: Patients with high-SI image HCC showed favorable long-term survival after curative surgery. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gd-EOB-DTPA-enhanced MRI; Hepatocellular carcinoma; high-signal-intensity; surgical outcome

Mesh:

Substances:

Year:  2019        PMID: 31366509     DOI: 10.21873/anticanres.13583

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study.

Authors:  Chenyi Rao; Xinquan Wang; Minda Li; Guofeng Zhou; Hongmei Gu
Journal:  BMC Med Imaging       Date:  2020-04-28       Impact factor: 1.930

2.  Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Daisuke Abo; Hirofumi Kamachi; Akinobu Taketomi
Journal:  JGH Open       Date:  2020-10-30

3.  Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.

Authors:  Osman Öcal; Michael Ingrisch; Muzaffer Reha Ümütlü; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Br J Cancer       Date:  2021-10-22       Impact factor: 7.640

4.  Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.

Authors:  Ryu Sasaki; Kazuyoshi Nagata; Masanori Fukushima; Masafumi Haraguchi; Satoshi Miuma; Hisamitsu Miyaaki; Akihiko Soyama; Masaaki Hidaka; Susumu Eguchi; Masaya Shigeno; Mio Yamashima; Shinobu Yamamichi; Tatsuki Ichikawa; Yuki Kugiyama; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

5.  Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.

Authors:  Osman Öcal; Daniel Rössler; Antonio Gasbarrini; Thomas Berg; Heinz-Josef Klümpen; Irene Bargellini; Bora Peynircioglu; Otto van Delden; Christian Schulz; Kerstin Schütte; Roberto Iezzi; Maciej Pech; Peter Malfertheiner; Bruno Sangro; Jens Ricke; Max Seidensticker
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-20       Impact factor: 4.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.